Acknowledgement
This study was supported by a 2-year research grant from Pusan National University (2019-2021).
References
- Dolphin AC. The α2δ subunits of voltage-gated calcium channels. Biochim Biophys Acta 2013; 1828: 1541-9. https://doi.org/10.1016/j.bbamem.2012.11.019
- Deeks ED. Mirogabalin: first global approval. Drugs 2019; 79: 463-8. https://doi.org/10.1007/s40265-019-01070-8
- Deeks ED. Correction to: mirogabalin: first global approval. Drugs 2019; 79: 469. https://doi.org/10.1007/s40265-019-01082-4
- Kim KH, Seo HJ, Abdi S, Huh B. All about pain pharmacology: what pain physicians should know. Korean J Pain 2020; 33: 108-20. https://doi.org/10.3344/kjp.2020.33.2.108
- Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 2017; 16: 829-42. https://doi.org/10.1038/nrd.2017.178
- Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 2018;365: 573-82. https://doi.org/10.1124/jpet.117.247551
- Dolphin AC. Voltage-gated calcium channel α2δ subunits: an assessment of proposed novel roles. F1000Res 2018; 7: F1000 Faculty Rev-1830.
- Dolphin AC. Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond. Nat Rev Neurosci 2012; 13: 542-55. https://doi.org/10.1038/nrn3311
- Burnashev N. Calcium permeability of ligand-gated channels. Cell Calcium 1998; 24: 325-32. https://doi.org/10.1016/S0143-4160(98)90056-2
- Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 2011; 3: a003947. https://doi.org/10.1101/cshperspect.a003947
- D'Arco M, Margas W, Cassidy JS, Dolphin AC. The upregulation of α2δ-1 subunit modulates activity-dependent Ca2+ signals in sensory neurons. J Neurosci 2015; 35: 5891-903. https://doi.org/10.1523/JNEUROSCI.3997-14.2015
- Hoppa MB, Lana B, Margas W, Dolphin AC, Ryan TA. α2δ expression sets presynaptic calcium channel abundance and release probability. Nature 2012; 486: 122-5. https://doi.org/10.1038/nature11033
- Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007; 28: 220-8. https://doi.org/10.1016/j.tips.2007.03.005
- Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth 2018; 120: 1315-34. https://doi.org/10.1016/j.bja.2018.02.066
- Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2 δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect 2016; 4: e00205. https://doi.org/10.1002/prp2.205
- El-Awaad E, Pryymachuk G, Fried C, Matthes J, Isensee J, Hucho T, et al. Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4. Sci Rep 2019; 9: 16272. https://doi.org/10.1038/s41598-019-52655-y
- Brini M, Calì T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci 2014; 71:2787-814. https://doi.org/10.1007/s00018-013-1550-7
- Alcantara Montero A, Sanchez Carnerero CI, Goicoechea Garcia C. Emerging therapies in clinical development and new contributions for neuropathic pain. Rev Esp Anestesiol Reanim 2019; 66: 324-34. https://doi.org/10.1016/j.redar.2019.02.003
- Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res 2018; 11: 1559-66. https://doi.org/10.2147/JPR.S145999
- Alyoubi RA, Alshareef AA, Aldughaither SM, Aljaroudi AM, Alabdulwahed A, Alduraibi FM, et al. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: a systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract 2020. doi: 10.1111/ijcp.13744.
- Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 2016; 16: 1263-77. https://doi.org/10.1080/14737175.2016.1202764
- Merante D. The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned. Curr Med Res Opin 2020; 36: 661-6. https://doi.org/10.1080/03007995.2020.1725744
- Burgess J, Javed S, Frank B, Malik RA, Alam U. Mirogabalin besylate in the treatment of neuropathic pain. Drugs Today (Barc) 2020; 56: 135-49. https://doi.org/10.1358/dot.2020.56.2.3100504
- Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, et al. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev 2018; 7: 661-9. https://doi.org/10.1002/cpdd.448
- Tetsunaga T, Tetsunaga T, Nishida K, Misawa H, Takigawa T, Yamane K, et al. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. J Orthop Surg Res 2020; 15: 191. https://doi.org/10.1186/s13018-020-01709-3
- Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S. Longterm safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: results from an open-label extension of a multicenter randomized, double-blind, placebocontrolled trial. Medicine (Baltimore) 2020; 99: e21976. https://doi.org/10.1097/md.0000000000021976
- Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain 2019; 160: 1175-85. https://doi.org/10.1097/j.pain.0000000000001501
- Ye X, Gray E, Wang YF, Wang SJ. Cost-effectiveness of mirogabalin for the treatment of post-herpetic neuralgia in Taiwan. J Med Econ 2020; 23: 529-36. https://doi.org/10.1080/13696998.2020.1720694
- Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig 2019; 10: 1299-306 https://doi.org/10.1111/jdi.13013
- Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; DS5565-A-U201 US Phase II Study Investigators. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care 2014; 37: 3253-61. https://doi.org/10.2337/dc14-1044
- Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A; DS-5565-A-U201US Phase 2 Study Investigators. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med 2017; 18: 2198-207.
- Baba M, Kuroha M, Ohwada S, Murayama E, Matsui N. Results of mirogabalin treatment for diabetic peripheral neuropathic pain in Asian subjects: a phase 2, double-blind, randomized, placebo-controlled, study. Pain Ther 2020; 9: 261-78. https://doi.org/10.1007/s40122-020-00156-6
- Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Longterm safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig 2020; 11: 693-8. https://doi.org/10.1111/jdi.13178
- Hutmacher MM, Frame B, Miller R, Truitt K, Merante D. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol 2016; 56: 67-77. https://doi.org/10.1002/jcph.567
- Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin 2019; 35: 1825-35. https://doi.org/10.1080/03007995.2019.1629757
- Kim K, Isu T, Kokubo R, Iwamoto N, Morimoto D, Kawauchi M, et al. Therapeutic effect of mirogabalin on peripheral neuropathic pain due to lumbar spine disease. Asian Spine J 2020. doi: 10.31616/asj.2020.0136.
- Baba M, Takatsuna H, Matsui N, Ohwada S. Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: a phase III, open-label, 14-week study. J Pain Res 2020; 13: 1811-21. https://doi.org/10.2147/JPR.S255345
- Kato M, Tajima N, Shimizu T, Sugihara M, Furihata K, Harada K, et al. Pharmacokinetics and safety of a single oral dose of mirogabalin in Japanese subjects with varying degrees of renal impairment. J Clin Pharmacol 2018; 58: 57-63. https://doi.org/10.1002/jcph.974
- Yin OQ, Merante D, Truitt K, Miller R. Population pharmaco-kinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol 2016; 56: 203-12. https://doi.org/10.1002/jcph.584
- Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H. Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin. Clin Drug Investig 2018; 38: 1001-9. https://doi.org/10.1007/s40261-018-0692-7
- Dow J, Currie A, He L, Zaidi F, Zahir H. Effect of coadministration of metformin with mirogabalin: results from a phase 1, randomized, open-label, drug-drug interaction study. Int J Clin Pharmacol Ther 2018; 56: 451-8. https://doi.org/10.5414/cp203185
- Tachibana M, Yamamura N, Atiee GJ, Hsu C, Warren V, He L, et al. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: a phase 1, randomized, open-label, drug-drug interaction study. Br J Clin Pharmacol 2018; 84: 2317-24. https://doi.org/10.1111/bcp.13674
- Jansen M, Mendell J, Currie A, Dow J, He L, Merante D, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of mirogabalin when coadministered with lorazepam, zolpidem, tramadol, or ethanol: results from drug-drug interaction studies in healthy subjects. Clin Pharmacol Drug Dev 2018; 7: 597-612. https://doi.org/10.1002/cpdd.582
- Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect 2018; 6: e00418. https://doi.org/10.1002/prp2.418
- Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, et al. Abuse potential of mirogabalin in recreational polydrug users. Ther Adv Drug Saf 2019; 10: 2042098619836032.
- Takahashi S, Ogata A, Nakamura M. A probable case of mirogabalin-induced neutropenia. Cureus 2020; 12: e10182.
- Matsuda KM, Tanaka-Mizutsugu H, Kishi Y, Hino H, Kagami S. A case of trigeminal trophic syndrome responding to mirogabalin. Eur J Dermatol 2020. doi: 10.1684/ejd.2020.3746.
- Kumar P, Thomas J. Trigeminal trophic syndrome. Indian J Dermatol 2014; 59: 75-6. https://doi.org/10.4103/0019-5154.123506
- Kitano Y, Wakimoto S, Tamura S, Kubota K, Domon Y, Arakawa N, et al. Effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons. Pharmazie 2019; 74: 147-9.
- Domon Y, Kitano Y, Makino M. Analgesic effects of the novel α2δ ligand mirogabalin in a rat model of spinal cord injury. Pharmazie 2018; 73: 659-61.
- Murasawa H, Kobayashi H, Saeki K, Kitano Y. Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain. Psychopharmacology (Berl) 2020; 237: 189-97. https://doi.org/10.1007/s00213-019-05356-3
- Murasawa H, Kobayashi H, Yasuda SI, Saeki K, Domon Y, Arakawa N, et al. Anxiolytic-like effects of mirogabalin, a novel ligand for α2δ ligand of voltage-gated calcium channels, in rats repeatedly injected with acidic saline intramuscularly, as an experimental model of fibromyalgia. Pharmacol Rep 2020; 72: 571-9. https://doi.org/10.1007/s43440-020-00103-4
- Saeki K, Yasuda SI, Kato M, Kano M, Domon Y, Arakawa N, et al. Analgesic effects of mirogabalin, a novel ligand for α2δ subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia. Naunyn Schmiedebergs Arch Pharmacol 2019; 392: 723-8. https://doi.org/10.1007/s00210-019-01628-z
- Iwai T, Kikuchi A, Oyama M, Watanabe S, Tanabe M. Mirogabalin prevents repeated restraint stress-induced dysfunction in mice. Behav Brain Res 2020; 383: 112506. https://doi.org/10.1016/j.bbr.2020.112506
- Kitano Y, Kai K, Yamamura N, Yoshiba S, Kuroha M. [Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg·5 mg·10 mg·15 mg)]. Nihon Yakurigaku Zasshi 2019; 154: 352-61. Japanese. https://doi.org/10.1254/fpj.154.352
- Gong N, Park J, Luo ZD. Injury-induced maladaptation and dysregulation of calcium channel α2δ subunit proteins and its contribution to neuropathic pain development. Br J Pharmacol 2018; 175: 2231-43. https://doi.org/10.1111/bph.13930
- Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49: 661-9. https://doi.org/10.2165/11536200-000000000-00000
Cited by
- Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit vol.14, pp.2, 2021, https://doi.org/10.3390/ph14020112